AnalystsTiago FauthTiago Fauth's Stock Forecasts
AnalystsTiago Fauth
Sectors:
Analyst Ranking
Bottom 4%
#4390 out of 4552 analysts
Average Return
-10.3%
Win Rate
29%25 out of 87
Risk vs Reward
Poor
Good
Tiago Fauth's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Absci CorpABSI | +352.14% | $1.17 | $5.29 | 2023-05-15 - 2024-04-17 | Buy |
Prometheus Biosciences IncRXDX | +299.88% | $48.39 | $193.50 | 2022-08-11 - 2023-04-18 | Buy |
Alx Oncology Holdings IncALXO | +182.19% | $5.39 | $15.21 | 2023-03-09 - 2024-03-08 | Buy |
Ventyx Biosciences IncVTYX | +159.06% | $14.85 | $38.47 | 2022-05-08 - 2023-05-08 | Buy |
Prometheus Biosciences IncRXDX | +137.98% | $50.00 | $118.99 | 2022-03-09 - 2023-03-09 | Buy |
Tiago Fauth Analyst Color
Get additional color on Tiago Fauth's coverage of popular stocks
Tiago Fauth's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Aerovate Therapeutics IncAVTE | 1 | Strong Buy | $35.00 | +55.56% | Maintains | 17 days ago |
Insmed IncINSM | 1 | Strong Buy | $55.00 | +110.08% | Maintains | 17 days ago |
United Therapeutics CorpUTHR | 2 | Strong Buy | $325.00 | +38.12% | Maintains | a month ago |
Alnylam Pharmaceuticals IncALNY | 2 | Hold | $161.00 | +10.79% | Maintains | 2 months ago |
Keros Therapeutics IncKROS | 1 | Strong Buy | $60.00 | +1.23% | Initiates Coverage On | 4 months ago |
Ultragenyx Pharmaceutical IncRARE | 5 | Strong Buy | $72.00 | +63.23% | Initiates Coverage On | 4 months ago |
Ventyx Biosciences IncVTYX | 5 | Buy | $62.00 | +1,315.53% | Maintains | 8 months ago |
Ascendis Pharma AASND | 13 | Hold | $89.00 | -37.40% | Assumes | 10 months ago |
Viridian Therapeutics IncVRDN | 3 | Buy | $51.00 | +238.20% | Assumes | 10 months ago |
Biomarin Pharmaceutical IncBMRN | 7 | Buy | $120.00 | +32.64% | Assumes | 10 months ago |
23andme Holding CoME | 6 | Buy | $6.00 | +1,585.39% | Reiterates | a year ago |
Immunovant IncIMVT | 4 | Sell | $4.00 | -85.93% | Reiterates | a year ago |
Vectivbio Holding AgVECT | 2 | Hold | $17.00 | +0.89% | Downgrades | a year ago |
Absci CorpABSI | 4 | Buy | $14.00 | +164.65% | Reiterates | a year ago |
Spruce Biosciences IncSPRB | 3 | Buy | $4.00 | +466.57% | Reiterates | a year ago |
Kura Oncology IncKURA | 5 | Buy | $26.00 | +44.52% | Reiterates | a year ago |
Abcellera Biologics IncABCL | 7 | Buy | $28.00 | +614.29% | Maintains | a year ago |
Apellis Pharmaceuticals IncAPLS | 9 | Hold | $81.00 | +68.64% | Maintains | a year ago |
Prometheus Biosciences IncRXDX | 5 | Hold | $200.00 | N/A | Downgrades | a year ago |
Humanigen IncHGENQ | 3 | Sell | $0.50 | N/A | Reiterates | a year ago |
Bioatla IncBCAB | 4 | Hold | $8.00 | N/A | Reiterates | a year ago |
Pyxis Oncology IncPYXS | 2 | Buy | $14.00 | N/A | Reiterates | a year ago |
Alx Oncology Holdings IncALXO | 2 | Buy | $34.00 | N/A | Maintains | a year ago |
Galecto IncGLTO | 2 | Buy | $6.00 | N/A | Reiterates | a year ago |
Exelixis IncEXEL | 1 | Buy | $29.00 | N/A | Initiates Coverage On | a year ago |
Omniab IncOABI | 1 | Buy | $13.00 | N/A | Initiates Coverage On | a year ago |
Editas Medicine IncEDIT | 2 | Hold | $13.00 | N/A | Downgrades | a year ago |
Forma Therapeutics Holdings IncFMTX | 2 | Hold | $20.00 | N/A | Downgrades | 2 years ago |
Inflarx NvIFRX | 3 | Sell | $2.00 | N/A | Maintains | 2 years ago |
Argenx SeARGX | 2 | Hold | $340.00 | N/A | Maintains | 2 years ago |
Iveric Bio IncISEE | 1 | Buy | $18.00 | N/A | Maintains | 3 years ago |
Arena Pharmaceuticals IncARNA | 1 | Buy | $98.00 | N/A | Maintains | 3 years ago |
Amgen IncAMGN | 1 | Buy | $259.00 | N/A | Maintains | 3 years ago |
Intercept Pharmaceuticals IncICPT | 1 | Hold | $59.00 | N/A | Downgrades | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.